PMID- 24889280
OWN - NLM
STAT- MEDLINE
DCOM- 20150611
LR  - 20181202
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 30
IP  - 10
DP  - 2014 Oct
TI  - Impact of socio-economic factors on the long-term effectiveness of 
      antihypertensive treatment with an angiotensin II receptor blocker: an 
      observational study.
PG  - 1947-55
LID - 10.1185/03007995.2014.929096 [doi]
AB  - OBJECTIVE: To investigate the role of socio-economic factors on the therapeutic 
      effectiveness of and therapeutic adherence to the angiotensin II receptor blocker 
      (ARB) olmesartan (OM) alone or in combination with hydrochlorothiazide in the 
      treatment of arterial hypertension. RESEARCH DESIGN AND METHODS: In a 
      multi-center, open-label, prospective and long-term observational study, data 
      from hypertensive patients treated with OM were analyzed at baseline, month 3 and 
      month 12 within the context of patients' socio-economic status (SES), determined 
      using pre-defined criteria by physicians in outpatient practices and including 
      multivariate analysis. RESULTS: Overall, 7724 patients were assigned to three 
      subgroups representing low, medium and high socio-economic status. Baseline 
      conditions differed significantly between the subgroups. Patients of low SES had 
      worse nutritional habits, less physical activity and more concomitant medication 
      compared to patients of high SES. Cardiovascular risk factors were more common in 
      the low SES group as were concomitant diseases such as heart failure, coronary 
      heart disease, atherosclerosis and renal failure. OM therapy led to a significant 
      decrease in blood pressure (23.0/11.6 mmHg) in all patients. The blood pressure 
      target of <140/90 mmHg was achieved in about 70% of the documented population. 
      Effectiveness was comparable between patients with low, medium or high SES. 
      Treatment adherence was high in the overall population with only minor 
      differences between the subgroups. In total the incidence of adverse events (AEs) 
      was 1.6% documented in 98 patents (1.3%) during the course of the study. Of this 
      total number only 1.0% was related to the drug, matching the percentage expressed 
      in the Summary of Product Characteristics (SmPC). CONCLUSIONS: The ARB OM is 
      effective and well tolerated in all patients, irrespective of their 
      socio-economic status. The risk status and the established cardiovascular disease 
      of hypertensive patients are strongly influenced by the SES. To validate these 
      interesting data a randomized controlled trial is needed.
FAU - Scholze, Jurgen
AU  - Scholze J
AD  - Medizinische Universitatspoliklinik, Campus Mitte, Charite-Universitatsmedizin 
      Berlin , Germany.
FAU - Weinstock, Alexander
AU  - Weinstock A
FAU - Kirchner, Florian
AU  - Kirchner F
FAU - Limberg, Roger
AU  - Limberg R
FAU - Kreutz, Reinhold
AU  - Kreutz R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140715
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Tetrazoles)
RN  - 8W1IQP3U10 (olmesartan)
SB  - IM
MH  - Aged
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/epidemiology
MH  - Female
MH  - Germany/epidemiology
MH  - Humans
MH  - *Hypertension/drug therapy/epidemiology
MH  - Imidazoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Socioeconomic Factors
MH  - Tetrazoles/*therapeutic use
MH  - Time
OTO - NOTNLM
OT  - Angiotensin II receptor blocker
OT  - Cardiovascular risk factors
OT  - Hypertension
OT  - Olmesartan
OT  - Socio-economic status
EDAT- 2014/06/04 06:00
MHDA- 2015/06/13 06:00
CRDT- 2014/06/04 06:00
PHST- 2014/06/04 06:00 [entrez]
PHST- 2014/06/04 06:00 [pubmed]
PHST- 2015/06/13 06:00 [medline]
AID - 10.1185/03007995.2014.929096 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2014 Oct;30(10):1947-55. doi: 10.1185/03007995.2014.929096. 
      Epub 2014 Jul 15.